Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2011, Article ID 847393, 6 pages
http://dx.doi.org/10.4061/2011/847393
Review Article

Myasthenia Gravis: A Review of Available Treatment Approaches

1Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
2Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway

Received 14 April 2011; Accepted 11 August 2011

Academic Editor: Renato Mantegazza

Copyright © 2011 Nils Erik Gilhus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. B. Andersen, A. Engeland, J. F. Owe, and N. E. Gilhus, “Myasthenia gravis requiring pyridostigmine treatment in a national population cohort,” European Journal of Neurology, vol. 17, no. 12, pp. 1445–1450, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. F. Owe, A. K. Daltveit, and N. E. Gilhus, “Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 77, no. 2, pp. 203–207, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. N. E. Gilhus, “Autoimmune myasthenia gravis,” Expert Review of Neurotherapeutics, vol. 9, no. 3, pp. 351–358, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. I. Leite, S. Jacob, S. Viegas et al., “IgG1 antibodies to acetylcholine receptors in “seronegative” myasthenia gravis,” Brain, vol. 131, no. 7, pp. 1940–1952, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. I. Leite, P. Waters, and A. Vincent, “Diagnostic use of autoantibodies in myasthenia gravis,” Autoimmunity, vol. 43, no. 5-6, pp. 371–379, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. Jaretzki III, R. J. Barohn, R. M. Ernstoff et al., “Myasthenia gravis: recommendations for clinical research standards,” Neurology, vol. 55, no. 1, pp. 16–23, 2000. View at Google Scholar · View at Scopus
  7. A. Evoli, “Acquired myasthenia gravis in childhood,” Current Opinion in Neurology, vol. 23, no. 5, pp. 536–540, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. M. Hoff, A. K. Daltveit, and N. E. Gilhus, “Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care,” European Journal of Neurology, vol. 14, no. 1, pp. 38–43, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. McGrogan, S. Sneddon, and C. S. De Vries, “The incidence of myasthenia gravis: a systematic literature review,” Neuroepidemiology, vol. 34, no. 3, pp. 171–183, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. G. O. Skeie, S. Apostolski, A. Evoli et al., “Guidelines for treatment of autoimmune neuromuscular transmission disorders,” European Journal of Neurology, vol. 17, no. 7, pp. 893–902, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. N. E. Gilhus, “Acute treatment for myasthenia gravis,” Nature Reviews Neurology, vol. 7, no. 3, pp. 132–134, 2011. View at Publisher · View at Google Scholar · View at PubMed
  12. I. Elovaara, S. Apostolski, P. van Doorn et al., “EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases,” European Journal of Neurology, vol. 15, no. 9, pp. 893–908, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. Gajdos, S. Chevret, and K. Toyka, “Plasma exchange for myasthenia gravis and Intravenous immunoglobulin for myasthenia gravis,” The Cochrane Library, no. 1, Article ID CD002277, 2009. View at Publisher · View at Google Scholar · View at PubMed
  14. A. Evoli, M. R. Bianchi, R. Riso et al., “Response to therapy in myasthenia gravis with anti-MuSK antibodies,” Annals of the New York Academy of Sciences, vol. 1132, pp. 76–83, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. Jani-Acsadi and R. P. Lisak, “Myasthenia gravis,” Current Treatment Options in Neurology, vol. 12, no. 3, pp. 231–243, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. V. Kumar and H. J. Kaminski, “Treatment of myasthenia gravis,” Current Neurology and Neuroscience Reports, vol. 11, pp. 89–96, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. B. M. Conti-Fine, M. Milani, and H. J. Kaminski, “Myasthenia gravis: past, present, and future,” Journal of Clinical Investigation, vol. 116, no. 11, pp. 2843–2854, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. D. B. Sanders and A. Evoli, “Immunosuppressive therapies in myasthenia gravis,” Autoimmunity, vol. 43, no. 5-6, pp. 428–435, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. Palace, J. Newsom-Davis, and B. Lecky, “A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis,” Neurology, vol. 50, no. 6, pp. 1778–1783, 1998. View at Google Scholar · View at Scopus
  20. D. B. Sanders and Z. A. Siddiqi, “Lessons from two trials of mycophenolate mofetil in myasthenia gravis,” Annals of the New York Academy of Sciences, vol. 1132, pp. 249–253, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. R. S. A. Tindall, J. T. Phillips, J. A. Rollins, L. Wells, and K. Hall, “A clinical therapeutic trial of cyclosporine in myasthenia gravis,” Annals of the New York Academy of Sciences, vol. 681, pp. 539–551, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Benveniste and D. Hilton-Jones, “The role of rituximab in the treatment of myasthenia gravis,” European Neurology Review, vol. 5, pp. 95–100, 2010. View at Google Scholar
  23. N. Minami, N. Fujiki, S. Doi et al., “Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis,” Journal of the Neurological Sciences, vol. 300, no. 1-2, pp. 59–62, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. K. Kondo, “Optimal therapy for thymoma,” Journal of Medical Investigation, vol. 55, no. 1-2, pp. 17–28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. N. E. Gilhus, J. A. Aarli, R. W. C. Janzen, H. F. Otto, E. Fasske, and R. Matre, “Skeletal muscle antibodies in patients with a thymic tumour but without myasthenia gravis,” Journal of Neuroimmunology, vol. 8, no. 2-3, pp. 69–78, 1985. View at Google Scholar
  26. G. S. Gronseth and R. J. Barohn, “Thymectomy for autoimmune myasthenia gravis: an evidence-based review,” Neurology, vol. 55, no. 1, pp. 7–15, 2000. View at Google Scholar · View at Scopus
  27. R. Mantegazza, F. Baggi, P. Bernasconi et al., “Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients,” Journal of the Neurological Sciences, vol. 212, no. 1-2, pp. 31–36, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Hoff, A. K. Daltveit, and N. E. Gilhus, “Myasthenia gravis: consequences for pregnancy, delivery, and the newborn,” Neurology, vol. 61, no. 10, pp. 1362–1366, 2003. View at Google Scholar · View at Scopus
  29. A. Polizzi, S. M. Huson, and A. Vincent, “Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis,” Teratology, vol. 62, no. 5, pp. 332–341, 2000. View at Google Scholar · View at Scopus
  30. E. Fostieri, K. Kostelidou, K. Poulas, and S. J. Tzartos, “Recent advances in the understanding and therapy of myasthenia gravis,” Future Neurology, vol. 1, pp. 799–817, 2006. View at Google Scholar
  31. J. Lindstrom, J. Luo, and A. Kuryatov, “Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains,” Annals of the New York Academy of Sciences, vol. 1132, pp. 29–41, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. Y. Matsumoto, H. Matsuo, H. Sakuma et al., “CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis,” Journal of Immunology, vol. 176, no. 8, pp. 5100–5107, 2006. View at Google Scholar · View at Scopus